期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 60, 期 5, 页码 1994-2005出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.6b01733
关键词
-
资金
- Ministry of Science and Technology of China [2016YFA0501100]
- National Science Fund for Distinguished Young Scholars [31625008]
- National Natural Science Foundation of China [21302106, 81573277, 81622042, 81361120405, 21532004, 31570733]
- Tsinghua University Initiative Scientific Research Program
- National Institutes of Health [RO1A1116466]
Drug-resistant malarial strains have been continuously emerging recently, which posts a great challenge for the global health. Therefore, new antimalarial drugs with novel targeting mechanisms are urgently needed for fighting drug-resistant malaria. NADH-ubiquinone oxidoreductase of Plasmodium falciparum (PfNDH2) represents a viable target for antimalarial drug development. However, the absence of structural information on PfNDH2 limited rational drug design and further development. Herein, we report high resolution crystal structures of the PfNDH2 protein for the first time in Apo-, NADH-, and RYL-552 (a new inhibitor) bound states. The PfNDH2 inhibitor exhibits excellent potency against both drug -resistant strains in vitro and parasite-infected mice in vivo via a potential allosteric mechanism. Furthermore, it was found that the inhibitor can be used in combination with dihydroartemisinin (DHA) synergistically. These findings not only are important for malarial PfNDH2 protein-based drug development but could also have broad implications for other NDH2-containing pathogenic microorganisms such as Mycobacterium tuberculosis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据